

(12) UK Patent Application (19) GB (11) 2 1 1 1 0 6 7 A

(21) Application No 8231041
(22) Date of filing
29 Oct 1982

(30) Priority data
(31) 316922
(32) 30 Oct 1981
(33) United States of America
(US)

(43) Application published
29 Jun 1983
(51) INT CL³ C08G 18/65
18/48 18/75

(52) Domestic classification
C3R 32A 32D16A
32D16B 32D16C
32D16D 32D6C 32D6L
32E2A 32E2Y 32G2A
32G2C 32G2Y 32H10
32H5AX 32H5AY
32H5B2 32H5BY 32H8
32H9A 32J1A 32J1X
32J1Y 32J3A 32J3B
32J3X 32J3Y 32KH
32KL C11 C12 C24 C25
C28X C9N C9Q L1B
L2C1 L2CX L3A L3B L6F
LX SM W
U1S 1035 1036 1573
1660 3001 3048 3052
3053 C3R

(56) Documents cited
GB A 2024233
GB 1529319
GB 1351774
GB 1351773
GB 1240116
GB 1075467
GB 0980435

(58) Field of search
C3R

(71) Applicant
Thermo Electron
Corporation
(USA—Massachusetts)
101 First Avenue
Waltham
Massachusetts 02154
United States of
America

(72) Inventor
Michael Szycher


(74) Agent and/or Address for
Service
Stevens Hewlett and
Perkins
5 Quality Court
Chancery Lane
London WC2A 1HZ

(54) Extrudable polyurethane for material.
prosthetic devices

(57) Reaction product of an aliphatic or cycloaliphatic diisocyanate, a poly-tetra methylene ether glycol and 1,4 butane diol. The diisocyanate is selected from hexamethylene diisocyanate, isophorone diisocyanate, trimethylhexamethylene diisocyanate, dicyclohexylmethane diisocyanate and dimer acid diisocyanate. The polytetramethylene ether glycol generally has a molecular weight of 500 to 5000. The resulting polymers have thromboresistant properties, a long flexural life and are extrudable. The polyurethane polymer is ideal for forming transvenous cardiac pacemaker leads, blood bags, intravenous and intra-arterial catheters and tubing, and other shaped devices which must be formed of a blood compatible

GB 2 1 1 1 0 6 7 A

2111067



SPECIFICATION

Extrudable polyurethane for prosthetic devices

5 BACKGROUND OF THE INVENTION 5

Significant advances have been made in recent years in development of vascular prosthesis. For example, U.S. Patent 4,131,604 to Szycher entitled Polyurethane Elastomer For Heart Assist Devices discloses a family of polyurethanes with excellent properties which can be used to form moldable prosthetic devices. One deficiency of the polyurethane disclosed in that patent
10 however is that those polyurethanes are not extrudable. There are many prosthetic devices as well as other devices, which must be blood compatible which can only be manufactured efficiently by extrusion or blow molding. 10

It should be apparent that devices such as pacemaker leads, blood bags, catheters, and I.V. tubing must be formed of a material that meets a number of criteria. The most significant
15 criteria is that the material from which such devices are fabricated must be hemocompatible. That is, the material should not induce the formation of a thrombus which can embolize into the peripheral bloodstream. Of course, the material must be non-toxic. In addition to the foregoing, it is desirable that materials for devices to be used in manufacturing vascular prosthesis possess a high degree of resiliency, strength and an ability to flex without breakage. As is mentioned
20 above for the formation of certain devices, it is desirable that the material be extrudable. 20

SUMMARY OF THE INVENTION

This invention relates to a family of extrudable polyurethane polymers specifically developed for use in devices that require a high degree of blood compatibility. The polymers can be
25 characterized as essentially linear, segmented, aliphatic polyurethane elastomers. This family of polymers, being aliphatic and polyether-based with 100% urethane linkages in the molecular backbone, exhibit superior flexural life, outstanding hydrolytic stability, and a high degree of blood compatibility. In addition to the foregoing, the polymers can be pelletized and extruded to form a variety of shaped devices such as cardiac pacemaker leads, blood bags, catheters and
30 I.V. tubing. This unusual combination of properties make this family of polymers useful in devices requiring blood contact surfaces. 30

It is therefore an object of this invention to provide an extrudable material suitable for use in forming devices that require a high degree of blood compatibility.

35 BRIEF DESCRIPTION OF THE DRAWING 35

The sole figure of the drawing is a diagram illustrating the process for extruding articles from the elastomer of the present invention.



DESCRIPTION OF THE PREFERRED EMBODIMENT

40 At the outset, the invention is described in its broadest overall aspects with a more detailed description following. The polyurethane elastomer of the present invention is a rubbery reaction product of aliphatic organic diisocyanates, high molecular weight polyether polyols and a specific low molecular weight glycol (chain extender). The low molecular weight glycol is 1,4 butane diol. 40

45 In addition to the foregoing required constituents, the reaction constituents preferably includes a catalyst and optionally an antioxidant and a lubricant for extrusion. 45



In general, polyurethane polymers are the condensation product of reactions between diisocyanates and compounds containing active hydrogen sites such as hydroxyl groups.

A diisocyanate is an isocyanate compound having a functionality of two. The polymerization
50 takes place in the presence of a difunctional hydroxyl compound (this can be either a simple glycol or a macromolecular glycol). 50




(polyurethane)


Examples of aliphatic diisocyanates useful in this invention are: hexamethylene diisocyanate (HDI),




isophorone diisocyanate (IPDI);
tri methyl hexamethylene diisocyanate (TMHDI),



dicyclohexyl methane diisocyanate (HMDI),



and dimer acid diisocyanate (DDI)




The preferred diisocyanate for forming polymers in accordance with this invention is dicyclohexyl methane diisocyanate (HMDI).

Although a number of aliphatic diisocyanates can be utilized in preparing a polymer in accordance with the present invention, numerous tests have indicated that the selection of the

high molecular weight polyol is limited to poly tetra methylene ether glycol (PTMEG) $H-(O-CH_2-CH_2-CH_2-CH_2)_n-OH$. Stated another way, this high molecular polyol is the only polyol which has been found to produce a polyurethane which is hemocompatible and possesses the other properties discussed above. In general, this glycol should have an average molecular weight between about 500 and 5000, preferably between 1000 and 3000. In the preferred embodiment of this invention PTMEG having a molecular weight of 2000 is utilized.

As was stated above, the chain extender for the polymer of the present invention is 1,4 butane diol ($HO-CH_2-CH_2-CH_2-CH_2-OH$).

The preferred polyurethane has the following structural formula:



where n_2 is an interger selected to give a molecular weight between 500-5000,

x is an integer from 1 to 5,

and n is an integer selected to give a number average molecular weight of 120,000 units, and a weight average molecular weight of 315,000 molecular weight units.

As can be seen from the above formula, the polymer of the present invention is composed of three repeating units, the diol, the diisocyanate and the macroglycol. The relationship of these repeating units to each other is determined by the physical characteristics desired. For example, for tubing which should be soft and elastomeric (70 Shore A), for each diol there are two diisocyanate repeating units and one macroglycol. To produce harder material, the ratio of diol to diisocyanate and macroglycol can be increased thereby resulting in a harder material. For example, for catheters (50 Shore D) two butane diol units are repeated for each isocyanate and each macroglycol.

The reactants are provided in approximately the molar amounts necessary to produce the foregoing polymer.

To obtain fully cured polyurethane castings in a reasonably short period of time, it is customary to incorporate into the mixture a suitable catalyst to promote the polymerization reaction. Suitable catalysts include N-methyl morpholine, trimethyl amine, triethyl amine, zinc octoate, dibutyl tin dilaurate and dioctyl tin dilaurate. Dioctyl tin dilaurate is the preferred catalyst.

The process in accordance with the present invention is represented diagrammatically in the sole figure of the drawing.

The polyurethane is prepared from two components which can be referred to as part A and part B. Part A is the aliphatic diisocyanate. Part B is comprised of the other constituents: a macroglycol (the polyether base), the low molecular weight chain extender, the catalyst, the antioxidant and the lubricant. Of course the catalyst, antioxidant and lubricant do not combine chemically as part of the polymer.

To form a polyurethane element, the proper stoichiometric proportions of part A and part B are emulsified by a mixer at room temperature to form a moderately reactive thixotropic mixture having a viscosity below about 2500 cps.

Since the emulsification introduces air into the reactive mixture, the air must be removed. The air bubbles are removed by placing a vessel containing the emulsion under a bell jar and evacuating the air from the bell jar with a suction device. The bell jar is evacuated to a pressure of about 0.3 microns and the mixture is kept under the bell jar about 8 minutes causing the mixture to appear to boil. After the emulsion is taken from the bell jar, it is allowed to stand until the exothermic reaction that is taking place brings it to a temperature of about 400°C.

At this point, the emulsion is preferably poured into a pan were it is allowed to flow to form uncured sheets. The pan with the sheets is then placed in an oven and heated at a temperature of at least 110°C. for four hours or more until the elastomer is cured. The sheets are then chopped up or pelletized in a standard pelletizer resulting in pellets approximately $\frac{1}{4}$ inch in

length. These pellet are then used in machinery suitable for an extrusion of the desired product.

In an optional embodiment of the invention, it is also possible to dissolve the pellets in a solvent such as dimethyl acetamide, tetrahydrofuran, 1,4 dioxane and m-pyrrol. The solution can then be used to make an article by the solvent casting method.

The invention is further illustrated by the following non-limiting example.

- 5 67.75 grams of dicyclohexyl methane diisocyanate (HMDI) was reacted with a mixture of the following five constituents: 229.2 grams of 2000 molecular weight poly tetra methylene ether glycol, 12.35 grams of 1,4, butane diol. This reaction mixture also contained 3.0 grams of a anti-oxidant. The anti-oxidant used is sold under the trade name IRGANOX 1010 by Ceiba Geigy. The chemical name of the anti-oxidant is tetrakis [methylene (3,5-di-tert-butyl-4-hydroxyhydrocinnamate)] methane. Also included in this reaction mixture was 0.5 grams of a lubricant sold under the trade name of GLYCOLUBE VL obtained from the Glyco Chemical Company of New York. 0.006 grams of a tin-based catalyst sold by Cosan Chemical Corporation of Carlstadt, New Jersey under their trade name COTIN 430 was also included.

- 15 The above constituents were mixed with the HMDI, deaerated until all entrained gases were removed. The mixture was then cured at 110°C for three hours under a nitrogen atmosphere in the form of sheets. The sheets were then chopped up in the standard pelletizer to form pellets suitable for extrusion. The physical properties of the cured elastomer was as follows: tensile strength 4500 psi minimum, elongation 650%, hardness (Shore A) 70-75.

- 20 The pellets were then processed in a laboratory extruder. Processing conditions were determined on a 1" diameter, 24/1 general purpose screw, as shown below:

	Rear °F	300	
	Middle °F	320	
	Front °F	320	
25	Die	330	25
	Throat	Water cooling	

Tubing, in sizes appropriate for use in pacemaker leads, was extruded. The tubing exhibited all the desirable physical characteristics required in these applications.

- 30 The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The present embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

CLAIMS

1. A polymer for use in molding devices requiring a high degree of blood compatibility, said polymer being a polyurethane elastomer and the reaction product of:
 - 40 a. a diisocyanate selected from the group consisting of isophorone diisocyanate, trimethyl hexamethylene diisocyanate, dicyclohexyl methane diisocyanate and dimer acid diisocyanate;
 - b. a poly tetra methylene ether polyol having a molecular weight in the range of 500-5000; and,
 - c. 1,4 butane diol.
- 45 2. The polymer as set forth in claim 1 wherein the diisocyanate is dicyclohexyl methane diisocyanate.
3. The polymer as set forth in claim 2 wherein said polymer is dissolved in a solvent.
4. The polymer as set forth in claim 2 wherein said polymer is in the form of pellets.
5. A two-component system for forming a polyurethane elastomer, said system comprising
 - 50 a) dicyclohexyl methane diisocyanate; and
 - b) a stoichiometric amount of polytetramethylene ether polyol and 1,4 butane diol.